Our findings suggest that apabetalone treatment may be able to reduce DUX4-associated pathology in FSHD patients and, combined with its established clinical safety and tolerability data, apabetalone is a promising clinical candidate for FSHD. The gene discussed is DUX4; the disease is facioscapulohumeral muscular dystrophy.